Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML IntergroupThomas Büchner, Richard F Schlenk, Markus Schaich, et al.
Annals of Hematology|October 24, 2012
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative GroupEva Lengfelder, Benjamin Hanfstein, Claudia Haferlach, et al.
Blood|July 24, 2013
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemiaSabrina Opatz, Harald Polzer, Tobias Herold, et al.
Blood|December 31, 2011
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor geneShuchi Agrawal-Singh, Fabienne Isken, Konstantin Agelopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Blood|November 30, 2016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelHartmut Döhner, Elihu Estey, David Grimwade, et al.
Blood|June 12, 2016
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemiaKlaus H Metzeler, Tobias Herold, Maja Rothenberg-Thurley, et al.
Blood|June 14, 2014
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosisTobias Herold, Klaus H Metzeler, Sebastian Vosberg, et al.
Blood|June 1, 2012
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemiaPhilipp A Greif, Annika Dufour, Nikola P Konstandin, et al.
Pageof 9